Optimal Duration of Olanzapine Add-on Therapy in Major Depression

Phase 3 Withdrawn Charite University, Berlin, Germany Eli Lilly and Company · collab

RandomizedParallel-groupTriple-blindTreatment

Summary

Evaluation of olanzapine versus placebo in the continuation therapy of subjects with major depression who had a response with additional olanzapine to an antidepressant.

Timeline

Start: 2007-10
Primary completion: 2008-01
Completion: 2008-04

Drugs

Evaluation	Drug	Modality	Dose	Route
Comparator	Olanzapine	Small molecule	5 mg	—

Indications

No indication recorded.